Navigation Links
Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
Date:8/5/2013

NEW YORK, Aug. 5, 2013 /PRNewswire/ -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today announced that Mark Pruzanski, MD, President and Chief Executive Officer, will present at the Wedbush Securities Life Sciences Management Access Conference in New York on Tuesday, August 13, 2013 at 9:45 a.m. ET.  A live webcast of the company's presentation will be available on the "Events" section of Intercept's investor website at http://ir.interceptpharma.com. A replay of the presentation will also be archived and available on Intercept's website for 2 weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA) is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC) in patients with an inadequate response to, or who are unable to tolerate, ursodiol, the only approved therapy for this indication. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to DSP. For more information about Intercept,
'/>"/>

SOURCE Intercept Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
4. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. Intercept Pharmaceuticals Closes $30 Million Series C Financing
6. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
7. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
8. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
9. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... LONDON , August 28, 2015 ... approach seamlessly connects people, technologies and care protoc ... improving outcomes and the cost of healthcare delivery   ... PHIA) today announced its presence at  ESC Congress 2015 , where ... Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that connect people ...
Breaking Medicine Technology:Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... SPEX ) announced today that it has signed letters ... pharmaceutical ingredients,to supply a portion of the D-tagatose used ... sugar as a treatment for Type 2 diabetes. Inalco ... D- tagatose for the Spherix New Drug Application (NDA) ...
... today announced that it submitted a supplemental New ... Administration (FDA) for approval of a new,indication for ... of patients with Chronic Obstructive,Pulmonary Disease (COPD). SYMBICORT ... asthma in patients 12 years and older., ...
Cached Medicine Technology:Spherix D-tagatose to be Supplied by Inalco SpA 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
(Date:8/29/2015)... ... 2015 , ... Vascular Health Sciences announced today that an ... HP, and that all claims and counterclaims have been irrevocably dismissed. , In ... the United States District Court for the Southern District of Texas for breach ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner ... they are applying for, they are unable to pass the initial drug test and ... testing policies in order to be able to hire long-term, skilled talent. (1) Will ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers how this software allows businesses to track product movement from beginning to end. ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for its adolescent residential, counseling, day treatment and intensive family based services. , ... standards for quality and its pursuit of excellence. As a nonprofit charity for ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... Haryana government claimed Monday that there was a minor improvement in ... the lowest figure in the country., ,Latest reports suggested that ... now at 822 females per thousand males, director general of health ... had recorded an abysmally low ratio of 819, which placed it ...
... had published a research report on recommendations to ... health-worker performance is a widespread problem for // ... of The Lancet researchers had reviewed the existing ... performance can be achieved., ,Millions of children ...
... Science is usually viewed with awe, not to mention a little ... people cannot understand, let alone hope to enter. Such an // ... the use of science., ,If the public is to have ... it should fist have a clear sense of what science can ...
... second largest number of HIV/AIDS afflicted people in the world ... of India are very real according to a World Economic ... businesses expect an effect on the business due to AIDS ... surveyed recently and 46 per cent report some ...
... The Office of Fair Trading is responsible for checking ... //manufacturers sell to the NHS. They have to monitor ... the prices should be reasonable. ,The Pharmaceutical ... monitors and legislates the agreement of the pricing and ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2
... Test, v1.5, an FDA-approved HIV-1 RNA assay, is ... used in the regulatory approval for HIV-1 therapies, ... 10 clinical laboratories worldwide. , The ... vitro nucleic acid amplification test for the quantification ...
... ADVANCE Rapid HIV-1/2 Antibody ... qualitative immunoassay to detect ... Virus Type 1 (HIV-1) ... in oral fluid, fingerstick ...
... CHS System takes the time proven technology ... ,The VHS® Supracondylar Cable Plate is designed ... femur fractures including periprosthetic fractures. The combination ... angle of the barrel and the plate ...
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: